IGF2 supports glioblastoma growth and immune evasion through a combination of tumor cell-intrinsic and -extrinsic mechanisms.

Saved in:
Bibliographic Details
Title: IGF2 supports glioblastoma growth and immune evasion through a combination of tumor cell-intrinsic and -extrinsic mechanisms.
Authors: Heemskerk KM; Cumming School of Medicine, University of Calgary, Calgary, Alberta.; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta., Assaf S; Cumming School of Medicine, University of Calgary, Calgary, Alberta.; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta., Hao X; Cumming School of Medicine, University of Calgary, Calgary, Alberta.; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta., Snelling S; Cumming School of Medicine, University of Calgary, Calgary, Alberta.; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta., Meode M; Cumming School of Medicine, University of Calgary, Calgary, Alberta.; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta., Hassam R; Cumming School of Medicine, University of Calgary, Calgary, Alberta.; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta., Cseh O; Cumming School of Medicine, University of Calgary, Calgary, Alberta., Kala S; Standard BioTools, Canada Inc, Markham, Ontario., Pemberton J; Standard BioTools, Canada Inc, Markham, Ontario., Chan JA; Cumming School of Medicine, University of Calgary, Calgary, Alberta.; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta., Cairncross JG; Cumming School of Medicine, University of Calgary, Calgary, Alberta.; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta., Forsyth P; Mofitt Cancer Center and Research Institute, Tampa, Florida (P.F.)., Yong VW; Cumming School of Medicine, University of Calgary, Calgary, Alberta., Mirzaei R; Department of Oncology, University of Alberta, Edmonton, Alberta.; Cross Cancer Institute, University of Alberta, Edmonton, Alberta., Weiss S; Cumming School of Medicine, University of Calgary, Calgary, Alberta.; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta., Zemp FJ; Cumming School of Medicine, University of Calgary, Calgary, Alberta.; Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta., Luchman HA; Cumming School of Medicine, University of Calgary, Calgary, Alberta.; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta.
Source: Neuro-oncology advances [Neurooncol Adv] 2025 Oct 15; Vol. 8 (1), pp. vdaf226. Date of Electronic Publication: 2025 Oct 15 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2632-2498
DOI:10.1093/noajnl/vdaf226